Related Experiment Videos
Endoscopic colorectal cancer screening: a cost-saving analysis.
1Department of Public Health, Erasmus University Rotterdam, The Netherlands. loeve@mgz.fgg.eur.nl
Journal of the National Cancer Institute
|April 6, 2000
Summary
Endoscopic colorectal cancer screening may be cost-neutral, potentially generating net savings by offsetting treatment costs. This finding depends on various factors, including screening frequency and diagnostic follow-up expenses.
Area of Science:
- Health Economics
- Oncology
- Preventive Medicine
Background:
- Cancer screening typically incurs net costs.
- This study investigates the economic viability of endoscopic colorectal cancer screening.
Purpose of the Study:
- To determine if savings from endoscopic colorectal cancer screening can offset its costs.
- To evaluate the cost-effectiveness of screening programs.
Main Methods:
- Utilized the MISCAN-COLON simulation model for U.S. population cost predictions over 30 years.
- Incorporated expert opinion and available data for epidemiological and cost parameters.
- Performed sensitivity analyses by varying key parameters.
Main Results:
- Every 5-year sigmoidoscopy screening could yield net savings by reducing cancer treatment costs.
- The break-even point for savings to exceed costs is estimated at 35-44 years.
- Net savings are sensitive to assumptions regarding disease natural history and program costs.
Conclusions:
- Endoscopic colorectal cancer screening may be cost-compensating.
- Further research is needed to refine understanding of disease dynamics, test accuracy, and associated costs.